Vyvanse Pumps Shire’s First Quarter
This article was originally published in The Pink Sheet Daily
Executive Summary
Company plans consumer ads to grow adult ADHD market.
You may also be interested in...
FDA Approves Shire’s Once-daily Vyvanse For Adult ADHD
British biopharma had pegged nearly one-third of drug’s sales to off-label adult usage.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.